Antigrel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antigrel

Property Description
Active ingredient Clopidogrel (as bisulfate salt)
Form Film-coated tablet
Pharmacological class Antiplatelet Agent (P2Y12 Inhibitor)
Common use Prevention of blood clots
Origin Synthetic (Thienopyridine derivative)

Antigrel is a prescription-only medicine whose primary role is to act as a Platelet Aggregation Inhibitor for cardiovascular health. This medication contains the synthetic active ingredient Clopidogrel, which is designed for systemic action to support healthy, unimpeded blood flow throughout the vascular network. Clopidogrel is classified within the drug class of antiplatelet agents.


What Type of Medicine is Antigrel (Clopidogrel)?

Antigrel belongs to the pharmacological class of Antithrombotic Drugs, specifically known as antiplatelet agents. Clopidogrel is a synthetic compound, a thienopyridine derivative, that is utilized for its focused action on platelets. The medication's fundamental purpose is to maintain fluidity in the circulation, primarily serving as a preventative cardiovascular medicine for individuals managing established risk factors. Clopidogrel is recognized as an essential medicine, underscoring its therapeutic importance.


Composition and General Purpose

The functional component of Antigrel is the active ingredient, Clopidogrel (utilized as the bisulfate salt), making it a single-ingredient product. Antigrel is an oral preparation administered via the oral route, packaged as a film-coated tablet to ensure stability and consistent absorption. The film coating is a factor intended to make the tablet easier to swallow and protect the core ingredients.

The general purpose of Antigrel is to prevent the formation of dangerous blood clots inside the arteries. It achieves this by making platelets less "sticky," thereby significantly reducing their tendency to cluster together (aggregate). This action is crucial for patients requiring sustained support for secondary prevention of major cardiovascular events.

What side effects are possible with Antigrel?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for Antigrel, based strictly on regulatory filings from government authorities.

Adverse Reactions

The most commonly reported adverse effects are related to bleeding and haematological disorders, which range in severity and frequency:

Frequency Category Examples of Adverse Reactions (Non-Exhaustive)
Common Bleeding events (e.g., haematoma, nosebleeds, gastrointestinal bleeding), Diarrhoea, Abdominal pain, Dyspepsia.
Uncommon Headache, Dizziness, Intracranial haemorrhage, Thrombocytopenia, Leucopenia, Rash, Pruritus.
Rare Vertigo.
Very Rare Thrombotic Thrombocytopenic Purpura (TTP), Acquired Haemophilia, Agranulocytosis, Severe Liver Failure, Anaphylactoid reactions, Serious skin reactions (e.g., Stevens-Johnson syndrome).

Serious Safety Considerations

The official safety profile highlights the risk of Severe and life-threatening bleeding, including fatal bleeding and Intracranial haemorrhage. Other serious, though very rare, adverse reactions include Thrombotic Thrombocytopenic Purpura (TTP), which requires urgent treatment and immediate discontinuation of the medicine, and Acquired Haemophilia.

Safety Restrictions and Precautions

Antigrel is Contraindicated (prohibited) for use in patients with active pathological bleeding (e.g., peptic ulcer, bleeding in the brain) and those with severe hepatic impairment (severe liver disease).

Caution is advised for specific populations, including:

  • Elderly patients (ge 75 years of age) due to an increased bleeding risk, especially when using a high loading dose.
  • Patients with renal impairment (kidney disease).
  • Patients with moderate hepatic disease (moderate liver disease).

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents state that an overdose of Antigrel (Clopidogrel) primarily results in an exaggeration of its antiplatelet effect. This leads to the central clinical manifestation of prolonged bleeding time and subsequent bleeding complications, which may present externally as unusual bruising or bleeding. The potential for these severe complications defines the risk profile of overexposure.


Emergency Action Mandates

Action Required When to Act
Call Emergency Services Immediately if the individual has collapsed, had a seizure, or is having trouble breathing.
Contact Poison Control For guidance in all cases of suspected overexposure.
Seek Immediate Medical Attention Required for any suspected overdose due to the severe risk of hemorrhage.

Since no specific chemical antidote is documented in the official labeling, management is entirely procedural and supportive. Regulatory guidance dictates that appropriate therapy must be considered if bleedings are observed. This supportive care often involves procedures such as platelet transfusions to counteract the excess antiplatelet effect and requires hospital monitoring. Furthermore, necessary diagnostic steps include blood cell count determination and other essential laboratory testing to assess the resulting coagulation status.

Therapeutic Uses of Antigrel

What Antigrel Treats: Main Uses and Benefits

Antigrel is applied in clinical settings that involve acute or disruptive symptom patterns to help with the management of symptoms related to systemic imbalance and vessel health. The active substance is relevant for patients in situations involving certain distressing symptoms associated with vessel health and episodes of acute systemic change.

It is commonly used across conditions presenting with episodic or fluctuating manifestations, such as situations involving symptoms related to heightened physiological activity, and where symptoms interfere with daily functioning. This medication helps address symptom clusters that may become intense or disruptive, especially in contexts marked by increased discomfort or tension.

Key Therapeutic Domains

This medication is often used to support patients facing common cardiovascular challenges, applied when symptoms create noticeable physiological strain and assistance with symptom stabilization is important. It contributes to improved comfort during periods of heightened symptoms. It offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Supports management of Noticeable Physiological Strain

This medication is used to provide supportive relief in clinical settings involving acute or unstable symptom patterns, helping to ease the overall symptom burden.

Eligibility and Restrictions for Use

Who can and cannot use Antigrel?

This section describes the officially documented rules for the eligibility and non-eligibility of patient populations for Antigrel (Clopidogrel), as defined by regulatory authorities.

Eligibility Classification Population Restriction Status Defined by Regulators
Absolute Contraindication Patients with active pathological bleeding (e.g., intracranial haemorrhage, peptic ulcer) Must not use
Absolute Contraindication Patients with Severe Hepatic Impairment Must not use
Absolute Contraindication Patients with Hypersensitivity to clopidogrel Must not use
Limited or Conditional Use Patients with Renal Impairment or Moderate Hepatic Disease Use with Caution (Limited Experience)
Conditional Use Patients known to be CYP2C19 Poor Metabolizers Consider Alternative Treatment

Age-Related Eligibility: Antigrel is approved for adult patients (aged 18 and older). The medicine is not established for safety or efficacy in the pediatric population (children and adolescents). Geriatric use generally requires no specific restrictions. Regarding pregnancy, use during labor or delivery is associated with an increased risk of maternal bleeding. It is unknown if the active ingredient is excreted into human milk during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Antigrel’s (Clopidogrel) interaction profile based on pharmacokinetic and pharmacodynamic constraints. This information is intended to describe documented patterns; it does not constitute clinical advice.

Documented Interaction Patterns

Interaction Type Interacting Substances/Classes Regulatory Constraint
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin), NSAIDs, Aspirin, SSRIs/SNRIs Increased risk of bleeding
Pharmacokinetic (CYP2C19) Omeprazole, Esomeprazole (CYP2C19 Inhibitors) Reduced antiplatelet activity; avoidance required
Pharmacokinetic (CYP2C8) Repaglinide (CYP2C8 Substrate) Increased systemic exposure; dose restriction applies

Formal Restrictions and Contraindications

Co-administration with the combination product Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir is formally contraindicated. Use is also contraindicated in patients with active pathological bleeding. Strong or moderate CYP2C19 inhibitors are recommended to be avoided due to reduced active metabolite exposure, which diminishes the intended platelet inhibition. Co-administration with Opioid Agonists is documented to delay and reduce Clopidogrel absorption.

Specific dosing and timing constraints apply to the co-administration of Repaglinide. Cautions also exist regarding potential interactions with Grapefruit Juice and for patients identified as CYP2C19 Poor Metabolizers, who may experience reduced drug effect.

Mechanism of Action

Irreversible Blockade of the Platelet Activation Receptor

The drug is an inactive prodrug that requires activation by liver enzymes, principally CYP2C19, before reaching its target. The active metabolite then acts to irreversibly block the P2Y12 receptor on the surface of platelets by forming a strong, covalent bond. This action functionally neutralizes the primary binding site for Adenosine Diphosphate (ADP), the key molecular messenger required to initiate full platelet activation.


Interruption of the Clotting Signal Cascade

By blocking the P2Y12 receptor, Antigrel interrupts the crucial signaling sequence that normally leads to the activation of the GP IIb/IIIa receptor. This interruption results in a sustained reduction in platelet aggregability, an effect that persists for the entire lifespan of the affected platelet (7-10 days).


Mechanism Variability Due to Prodrug Metabolism

The activation pathway is limited by a competing deactivation process (esterases). Furthermore, individuals with specific genetic variations in the CYP2C19 enzyme may produce less of the active metabolite, resulting in a functionally lower extent of P2Y12 inhibition.

Dosage and Administration Information

How to Use Antigrel: Official Administration Guidelines

Antigrel (Clopidogrel) is an oral antiplatelet medication whose usage is defined by official instructions regarding dosage, frequency, and specific administration conditions. The medicine is supplied as a film-coated tablet in strengths including 75 mg and 300 mg.


Official Dosing and Frequency

Administration generally follows a two-phase protocol. In acute settings, an initial loading dose of 300 mg or 600 mg may be administered orally to achieve a rapid effect, followed by the standard maintenance dose. The standard maintenance dose for long-term use is 75 mg taken once daily.


Administration Conditions and Timing

Instruction Official Guidance
Route of Administration Oral (PO) only.
Timing with Meals Can be administered with or without food.
Missed Dose Rule If missed by less than 12 hours, take immediately. If missed by more than 12 hours, skip the dose and take the next scheduled dose; do not double the dose.
Concomitant Use Generally used in combination with low-dose acetylsalicylic acid (ASA) for many high-risk conditions.

Population and Procedural Rules

Treatment duration varies by condition but is indicated for long-term use in established conditions. Regarding specific populations, no dose adjustment is typically required for patients with renal impairment, though caution is advised in cases of severe hepatic impairment. Furthermore, official guidance states that the medicine should be discontinued 7 days prior to elective surgery if an antiplatelet effect is not desired. The safety and efficacy of Antigrel are not established for use in the pediatric population.

Recent Clinical Evidence

The research evidence for Antigrel (Clopidogrel) comes primarily from clinical studies conducted by researchers. These studies focused on specific endpoints, mainly examining patterns related to outcomes associated with serious vascular events such as heart attack and stroke. The evidence describes what was observed in large groups of patients under specific, controlled research conditions.

Primary Research Areas

Extensive Randomized Controlled Trials (RCTs) were designed to examine outcomes in adults presenting with recent heart attack (Myocardial Infarction or MI) or unstable chest pain (Unstable Angina), a condition known as Acute Coronary Syndrome (ACS). Trials monitored patients who received the medication in combination with aspirin, exploring composite endpoints that combine cardiovascular death, non-fatal heart attack, and ischemic stroke. Specific research also explored outcomes related to Stent Thrombosis following coronary procedures.

Long-term RCTs were conducted to monitor outcomes in adults with established disease for Secondary Prevention, including a history of prior MI, prior Ischemic Stroke, or clinically symptomatic Peripheral Arterial Disease (PAD). These studies examined the incidence of recurrent vascular events over several years, exploring the durability of observed patterns.

Evidence in Specific Contexts and Uncertainties

This medication was also evaluated in patients with Atrial Fibrillation (AF) who were identified as unsuitable for standard treatments like Vitamin K Antagonists (VKA). The evidence in this area is limited to this specific subgroup. Studies have also explored the outcomes observed in special groups, such as older adults and those with comorbid conditions like diabetes mellitus, although subgroup findings were mixed or uncertain in some areas.

A key area of uncertainty relates to the influence of a person's genetic makeup, specifically the CYP2C19 enzyme, where the full clinical impact of these genetic differences remains unclear. Additionally, researchers continue to explore the effect of different antiplatelet therapy durations, as findings were mixed across studies regarding extended use.

Frequently Asked Questions (FAQ)

Common questions about Antigrel (FAQ)


Q: How quickly does Antigrel start working?

A: Official prescribing information indicates that after an initial loading dose, the active substance reaches its peak concentration in the body in approximately 30 to 60 minutes. However, a sustained antiplatelet effect is typically achieved after taking a daily maintenance dose for 3 to 7 days.


Q: What happens if I take too much Antigrel?

A: If too much of this medicine is taken (overdosage), regulatory documents caution that this can lead to an increase in bleeding time and potential bleeding complications. Regulatory information indicates that treatment for overdosage may involve measures such as platelet transfusion to help manage and reverse the antiplatelet effect.


Q: Can alcohol be consumed while taking Antigrel?

A: While regulatory documents do not list alcohol as a formal drug-drug interaction, official safety information indicates that the medication increases the general risk of bleeding. Factors like alcohol use may contribute to this risk, particularly gastrointestinal bleeding.


Q: What should I tell a healthcare provider before surgery if I take Antigrel?

A: It is important that healthcare providers, including surgeons and dentists, are made aware that the medication is being taken. Official procedural rules describe that the medication is typically discontinued five days before elective surgery if the antiplatelet effect (or blood thinning) is not wanted during the procedure.


Q: How long do most people take Antigrel for?

A: The duration of treatment is based on the medical condition being managed. For chronic conditions like established Peripheral Arterial Disease or secondary prevention after a stroke, the medicine is indicated for long-term use. Following acute events like a heart attack, it is often prescribed in combination with aspirin for at least 12 months, and sometimes longer.


Q: If I feel better, can I stop taking Antigrel?

A: Official warnings state that discontinuing the medication prematurely without clinical guidance is associated with an increased risk of serious cardiovascular events, such as heart attack and stroke. All decisions regarding stopping or changing treatment are part of a clinical treatment plan and should be reviewed by a qualified healthcare professional.


Q: Is it normal to bruise more easily while on Antigrel?

A: Yes, easier bruising, medically described as haematoma or blood collection under the skin, is listed as a commonly reported side effect. This occurs because the medicine increases the general risk of bleeding. Individuals experiencing excessive bruising or unexpected bleeding are encouraged to discuss these observations with a healthcare professional.


Q: Do I need a prescription to get Antigrel?

A: Yes, Antigrel (Clopidogrel) is classified as a human prescription drug by regulatory authorities. This means it requires a valid prescription from a licensed healthcare provider before it can be dispensed.


Q: Are there foods or drinks that interact with Antigrel?

A: Official warnings specifically advise caution regarding the consumption of Grapefruit Juice, as it has been noted to potentially affect how the medicine works in the body. Aside from this specific warning, there are no widespread, documented restrictions on general food consumption.


Q: What happens if I forget to take a dose of Antigrel?

A: If a dose is missed by less than 12 hours, the medicine’s instructions indicate it is to be taken immediately. If more than 12 hours have passed, the instructions describe skipping the missed dose and resuming the next dose at the regularly scheduled time; the guidelines advise against taking a double dose.


Q: Is Antigrel safe for long-term use?

A: Antigrel is specifically indicated for long-term use for certain conditions, such as the secondary prevention of cardiovascular events. Official clinical studies have monitored patients over extended periods to establish its profile. Regulatory oversight includes continuous monitoring of the medication's safety profile during its use, which includes long-term administration as indicated.


Q: Can Antigrel cause bleeding problems?

A: Yes, regulatory documents clearly state that the most common and serious adverse reactions related to this medicine involve bleeding. It is officially documented to increase the general risk of bleeding, which can range from minor issues like nosebleeds and bruises to more severe, even life-threatening events.


Q: Can women who are pregnant or breastfeeding take Antigrel?

A: While studies have not identified an association between the use of Antigrel during pregnancy and specific adverse birth outcomes, its use during labor or delivery is associated with an increased risk of bleeding in the mother. Official information also states it is unknown if the active ingredient is passed into human milk during lactation.


Q: Is it okay to take Antigrel with pain relievers like ibuprofen?

A: Official drug interaction warnings caution that Antigrel interacts with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), the drug class that includes ibuprofen. Taking them together is officially documented to increase the risk of bleeding, especially internal bleeding in the stomach or intestines.


Q: What should I avoid while taking Antigrel?

A: Official documents advise that specific substances may need to be avoided. This includes strong or moderate inhibitors of the CYP2C19 enzyme, such as certain stomach acid medications like omeprazole and esomeprazole. Additionally, concurrent use of NSAIDs and oral anticoagulants is generally cautioned against due to the documented increased risk of bleeding. Official documentation describes that the combination with stomach acid medications is often avoided in clinical practice.


Q: How long does Antigrel stay in the system after stopping it?

A: The blood-thinning effect of Antigrel is tied to the lifespan of the affected platelets, which is about 7 to 10 days. The antiplatelet effect on function is noted to gradually return to baseline values generally within 5 days after stopping the medication.


Q: Can Antigrel be split or crushed?

A: The official product information describes Antigrel as a film-coated tablet. Generally, film-coated tablets should be swallowed whole. As the product is a film-coated tablet, it is intended to be swallowed whole, and there are no official instructions confirming that the consistency of the dose is maintained if the tablet is altered.


Q: Does Antigrel cause dizziness or fatigue?

A: Official reports list dizziness and vertigo (a sensation of spinning) as uncommon side effects that may occur in up to 1% of patients. However, general fatigue or drowsiness is not listed among the most commonly reported side effects in the official product labeling.


Q: Why is Antigrel prescribed after a stent procedure?

A: The medication is prescribed after a stent procedure to reduce the risk of future major cardiovascular events, including heart attack and stroke. Research specifically explored outcomes related to stent thrombosis, which is the formation of a dangerous blood clot on the newly placed stent.


Q: Can Antigrel interact with stomach acid medications?

A: Yes, official regulatory documents specifically warn that certain types of stomach acid medications, known as Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole, can reduce the antiplatelet effectiveness of Antigrel. Patients are often advised to avoid this specific combination in clinical practice.


Q: What are the symptoms of an allergic reaction to Antigrel?

A: Antigrel is contraindicated for those with known hypersensitivity. Official adverse reaction reports list severe allergic reactions, such as anaphylactoid reactions (which may involve swelling or difficulty breathing), and serious skin reactions, like rashes or pruritus, as potential adverse events.


Q: Does Antigrel need to be taken at a specific time of day?

A: Official dosing instructions require the medicine to be taken once daily. It can be taken with or without food. Regulatory labeling does not contain specific instructions requiring the medicine to be taken at a particular time of day (e.g., morning or evening).


Q: Are there documented long-term side effects of Antigrel?

A: Regulatory documents list side effects by frequency based on data from clinical studies, some of which are long-term. These commonly reported effects include bleeding, diarrhoea, and abdominal pain. The official labeling, however, does not categorize these effects specifically as 'short-term' or 'long-term' categories.


Q: Does Antigrel affect blood pressure?

A: Official reports from clinical trials list hypertension (high blood pressure) as a common adverse event. Post-marketing surveillance also lists hypotension (low blood pressure) as a very rare reaction. It is important to note these are reported events and may not always be causally related to the medication itself.


Q: Is Antigrel linked to any digestive issues?

A: Yes, official side effect reports list several common digestive issues, including diarrhoea, abdominal pain, and dyspepsia (indigestion). The medication's overall safety profile also includes the documented risk of gastrointestinal bleeding.


Q: Why do doctors prescribe Antigrel instead of aspirin?

A: Official clinical studies have documented that in certain patient groups with a history of vascular events, the medication demonstrated a lower rate of a combined outcome (heart attack, stroke, or vascular death) compared to aspirin. For many acute conditions, the medication is actually prescribed in combination with aspirin.


Q: Is Antigrel used for preventing strokes?

A: Yes, Antigrel is officially indicated to reduce the rate of stroke. This use applies to patients who have a history of a recent heart attack, a recent stroke, or established peripheral arterial disease. It is used as a secondary prevention measure.

How should Antigrel be stored and disposed of?

How to Store and Dispose of Antigrel

Storage and disposal of Antigrel (Clopidogrel) must strictly follow the official conditions outlined in the regulatory labeling to maintain the product's quality.

Storage Requirements

Antigrel tablets must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). The product requires protection from moisture, excess heat, and light, and it must not be frozen. Keep the medicine in its original container, ensure the container is tightly closed, and always store it out of the sight and reach of children.

Disposal

Any unused or expired Antigrel must be disposed of according to local regulatory requirements. It is prohibited to flush this medicine down the sink or toilet unless specifically advised by official guidelines. Preferred disposal methods include community drug take-back programs or designated household waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antigrel found in:

A-Z Index: